Upadacitinib as a rescue therapy for steroid- and infliximab-refractory acute severe ulcerative colitis: short- and long-term effectiveness and safety in a multicenter cohort study.

In this multicenter cohort of patients with ASUC who failed intravenous corticosteroids and infliximab rescue, third-line upadacitinib was associated with a low colectomy rate and sustained response up to 1 year, with an acceptable safety profile.

upadacitinib may provide sufficient disease control to prevent or delay colectomy, or to serve as a bridge to alternative therapies.

In this retrospective multicenter cohort (11 centers), 50 patients with severe ulcerative colitis refractory to intravenous corticosteroids and infliximab received upadacitinib.